Hemispherx to charge $300 per week for Ampligen under treatment protocol beginning the week of May 26.
Executive Summary
HEMISPHERx TO CHARGE $300 PER WEEK FOR AMPLIGEN ON COST-RECOVERY BASIS for an open-label trial of the drug in chronic fatigue syndrome patients. The trial will initially treat 20 patients. The first patient has been identified and is set to receive the high-molecular weight double-stranded RNA I.V. drug the week of May 26. The patient was featured in a Philadelphia Inquirer article earlier in May; Philadelphia-based Hemispherx (formerly HEM Pharmaceuticals) previously has proved adept at gaining media coverage of Ampligen, as at a 1991 conference when the firm hired Broadgate Consultants to publicize a presentation of Phase II data.